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genotypes: (1) elav±GAL4/+; UAS±wild-type a-synuclein/+; (2) UAS±A30P
a-synuclein/elav±GAL4; and (3) UAS±A53T a-synuclein/elav±GAL4. Sections were
stained with haematoxylin and eosin. Time points monitored were 1, 10, 30 and 60 days. In
addition, serial 1-mm sections of glutaraldehyde-®xed heads from ¯ies of the same
genotypes prepared at 1, 30 and 60 days were stained with toluidine blue to highlight
degenerating cells. No evidence of excess neurodegeneration was detected using either
technique.
To evaluate dopaminergic cells of the dorsomedial cluster by tyrosine hydroxylase
immunostaining, serial 4-mm sections were cut to include the entire brain. Immuno-
positive cells at the level of the giant interneuron commissure, posterior to the fan-shaped
body, were counted in well oriented frontal sections at 1, 10, 30 and 60 days. At 1 day all
control and experimental sections contained four or ®ve cells in the delineated region. At
30 and 60 days all controls showed four or ®ve cells. At 30 and 60 days all a-synuclein-
expressing animals (a-synuclein, elav±GAL4 and a-synuclein, Ddc±GAL4 transhetero-
zygotes) showed 0 or 1 tyrosine-hydroxylase-positive cell in the de®ned region. Tyrosine-
hydroxylase-positive cells outside the dorsomedial cluster were present, and served as
internal controls for the immunostaining procedure. At least four, and usually between six
and ten brains were examined for wild-type a-synuclein and each mutant a-synuclein.
Controls included young and aged ¯ies of the genotypes elav±GAL4/+ and Ddc±GAL4/+.
We evaluated expression of a-synuclein and b-galactosidase on similar serial section
preparations. Quanti®cation was simpli®ed in these experiments because no clear cell-
body-associated a-synuclein or b-galactosidase immunoreactivity was observed in the
aged a-synuclein transgenic ¯ies at the times reported.
For histological examination of retinas, heads were ®xed in glutaraldehyde and
embedded in epon. Tangential retinal sections were prepared at a thickness of 1 mm and
stained with toluidine blue (Fig 4).
Standard electron microscopy was performed on brains from 25-day-old experimental
(UAS±A30P a-synuclein/elav±GAL4) and control (elav±GAL4/+) ¯ies. For immunoe-
lectron microscopy, pre-embedding immunohistochemistry with an Hrp-congugated
secondary antibody was performed on 60-day adult brains from experimental (UAS±
A30P a-synuclein/elav±GAL4) and control (elav±GAL4/+) ¯ies ®xed in 4% para-
formaldehyde with 0.5% glutaraldehyde. Tissue was post-®xed in osmium and embedded
in epon. Unstained ultrathin sections and ultrathin sections stained with uranyl acetate
and lead citrate were examined.
Climbing assay
The climbing assay was performed as described19,20. Forty ¯ies were placed in a plastic vial,
and gently tapped to the bottom of the vial. The number of ¯ies at the top of the vial was
counted after 18 s of climbing. Twenty trials were performed for each time point. The data
shown represent results from a cohort of ¯ies tested serially over 55 days. The experiment
was repeated three times, with independently derived transgenic lines. Similar results were
obtained from each experiment. The experiment was carried out under red light (Kodak
Safelight Filter 1A). Control ¯ies were of the genotype elav±GAL4/+. Experimental
animals were of the following genotypes: (1) elav±GAL4/+; UAS±wild-type a-synuclein/+;
(2) UAS±A30P a-synuclein/elav±GAL4; and (3) UAS±A53T a-synuclein/elav±GAL4.
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Helicobacter pylori infection is associated with a variety of clinical
outcomes including gastric cancer and duodenal ulcer disease1.
The reasons for this variation are not clear, but the gastric
physiological response is in¯uenced by the severity and anatomi-
cal distribution of gastritis induced by H. pylori. Thus, individuals
© 2000 Macmillan Magazines Ltd
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with gastritis predominantly localized to the antrum retain
normal (or even high) acid secretion2, whereas individuals with
extensive corpus gastritis develop hypochlorhydria and gastric
atrophy3, which are presumptive precursors of gastric cancer4.
Here we report that interleukin-1 gene cluster polymorphisms
suspected of enhancing production of interleukin-1-beta are
associated with an increased risk of both hypochlorhydria
induced by H. pylori and gastric cancer. Two of these polymorph-
ism are in near-complete linkage disequilibrium and one is a
TATA-box polymorphism that markedly affects DNA±protein
interactions in vitro. The association with disease may be
explained by the biological properties of interleukin-1-beta,
which is an important pro-in¯ammatory cytokine5 and a powerful
inhibitor of gastric acid secretion6,7. Host genetic factors that
affect interleukin-1-beta may determine why some individuals
infected with H. pylori develop gastric cancer while others do not.
H. pylori infects half of the world's population and has been
implicated in the pathogenesis of gastric cancer1, the second-most
common malignancy worldwide8. The mechanism of H. pylori-
induced carcinogenesis is not clear. The infection almost always
causes in¯ammation of the gastric mucosa, the distribution and
severity of which varies widely and affects the clinical outcome.
Gastritis that is con®ned to the antral region is associated with
excessive acid production and a high risk of duodenal ulcer disease2.
In contrast, gastritis involving the acid-secreting corpus region leads
to hypochlorhydria, progressive gastric atrophy3 and an increased
risk of gastric cancer4,9. These pre-cancerous changes are unfavour-
able to H. pylori growth and some gastric cancers arise long after the
infection has disappeared. Duodenal ulceration and gastric cancer
seem to be mutually exclusive outcomes of H. pylori infection that
cannot be explained by differences in bacterial virulence factors
alone, as virulent strains seem to be equally associated with both
conditions10,11. An alternative explanation is that host genetic factors
(in conjunction with bacterial and/or environmental factors) deter-
mine the immune and in¯ammatory responses to H. pylori infec-
tion. A critical factor in H. pylori-induced gastric carcinogenesis is
gastric acid secretion, which both in¯uences and is in¯uenced by
H. pylori-induced gastritis. If in¯ammation of the corpus mucosa is
severe, acid secretion is inhibited and eventually lost through the
destruction of gastric glands3. Furthermore, pharmacological inhi-
bition of acid secretion leads to the re-distribution of H. pylori-
induced gastritis with a reduced intensity of antral in¯ammation
and an increased intensity in the corpus, and may progress to gastric
atrophy in the long term12. Endogenous factors that suppress acid
secretion could also contribute to corpus gastritis and atrophy.
The interleukin-1 (IL-1) gene cluster on chromosome 2q contains
3 related genes within a 430-kilobase (kb) region, IL-1A, IL-1B and
IL-1RN, which encode the pro-in¯ammatory cytokines IL-1a and
IL-1b as well as their endogenous receptor antagonist IL-1ra
respectively5. IL-1b is upregulated in the presence of H. pylori and
is important in initiating and amplifying the in¯ammatory response
to this infection13±15. IL-1b is also a potent inhibitor of gastric acid
secretion6,7; on a molar basis it is estimated to be 100-fold more
potent than proton pump inhibitors and 6,000-fold more potent
Table 1 Estimated haplotype frequencies and linkage disequilibrium coef®cients
Haplotype* Disequilibrium²
Population Loci 1±1 1±2 2±1 2±2 1±3,4,5 2±3,4,5 D9 x2 p
...................................................................................................................................................................................................................................................................................................................................................................
GCR controls IL-1B 2 31=IL-1B 2 511 0.610 0.010 0.005 0.375 0.98 95.2 0.0001
(n  100) IL-1B 2 31=IL-1B  3954 0.420 0.200 0.380 0.000 -0.53 27.8 0.0001
IL-1B 2 31=IL-1RN 0.519 0.096 0.131 0.244 0.005 0.005 0.52 26.6 0.0001
IL ÿ 1B  3954=IL-1RN 0.495 0.295 0.155 0.045 0.010 0.000 -0.20 3.8 0.05
Low acid GCR IL-1B 2 31=IL-1B 2 511 0.422 0.000 0.022 0.556 0.96 41.4 0.0001
(n  45) IL-1B 2 31=IL-1B  3954 0.273 0.149 0.560 0.018 -0.27 3.3 0.07
IL-1B 2 31=IL-1RN 0.330 0.092 0.203 0.375 0.000 0.000 0.48 10.5 0.001
IL ÿ 1B  3954=IL-1RN 0.408 0.425 0.125 0.042 0.000 0.000 -0.17 1.4 0.24
Normal acid GCR IL-1B 2 31=IL-1B 2 511 0.681 0.017 0.000 0.302 0.95 52.1 0.0001
(n  58) IL-1B 2 31=IL-1B  3954 0.527 0.171 0.275 0.027 -0.20 2.3 0.13
IL-1B 2 31=IL-1RN 0.611 0.087 0.130 0.155 0.000 0.017 0.47 12.6 0.0004
IL ÿ 1B  3954=IL-1RN 0.561 0.223 0.180 0.018 0.017 0.000 -0.25 3.6 0.06
Gastric cancer controls IL-1B 2 31=IL-1B 2 511 0.699 0.002 0.000 0.298 1.00 426.6 0.0001
(n  429) IL-1B 2 31=IL-1B  3954 0.498 0.203 0.250 0.048 -0.16 11.2 0.0008
IL-1B 2 31=IL-1RN 0.612 0.084 0.109 0.185 0.005 0.004 0.51 112.6 0.0001
IL ÿ 1B  3954=IL-1RN 0.525 0.214 0.196 0.056 0.009 0.000 -0.07 2.1 0.14
Gastric cancer cases IL-1B 2 31=IL-1B 2 511 0.576 0.008 0.003 0.413 0.98 352.4 0.0001
(n  366) IL-1B 2 31=IL-1B  3954 0.418 0.166 0.352 0.063 -0.19 12.8 0.0003
IL-1B 2 31=IL-1RN 0.423 0.155 0.152 0.259 0.007 0.004 0.39 54.7 0.0001
IL ÿ 1B  3954=IL-1RN 0.413 0.350 0.162 0.064 0.007 0.004 -0.17 11.0 0.0009
...................................................................................................................................................................................................................................................................................................................................................................
Data given for pairs of IL-1 loci in gastric cancer relatives (GCR), gastric cancer cases and respective control populations.
* For all IL-1B loci, C is denoted by allele 1 and T is denoted by allele 2.
² D9  D=Dmax for association of most common alleles at each locus.
IL-1B–31T IL-1B–31C
LPS
     T    C         
Complex 1
Complex 2
Complex 3
1 2 3 4 5 6
Unlabelled probe
–
–
+
–
–
–
+
–
+ +
Lane 
Figure 1 Differential binding patterns between the T- and C-bearing alleles of the IL-1B
promoter. Nuclear extracts from fresh human monocytes stimulated for 30 min with
lipopolysaccharide (LPS) (+) show evidence of induction of DNA±protein complexes 1 and
2 on the IL-1B 2 31T oligonucleotide. Complex 3 and free probe were equivalent across
all lanes. Cold competition with a 100-fold excess of unlabelled probe (T) blocked the
formation of complex 1 (lane 3), whereas cross-competition with unlabelled IL-1B 2 31C
(C) only partially blocked complex 1 (lane 4). Results were similar with monocyte extracts
from three different donors.
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than H2 antagonists
16. Three diallelic polymorphisms in IL-1B
have been reported, all representing C±T base transitions, at
positions -511, -31 and +3954 base pairs (bp) from the tran-
scriptional start site17. There are con¯icting data regarding the
functional effects of these polymorphisms on IL-1b
production18,19. The IL-1RN gene has a penta-allelic 86-bp
tandem repeat (VNTR) in intron 2, of which the less common
allele 2 (IL-1RN*2) is associated with a wide range of chronic
in¯ammatory and autoimmune conditions17. IL-1RN*2 is asso-
ciated with enhanced IL-1b production in vitro19, but data
regarding its effects on IL-1ra production are contradictory20±22.
To determine whether these polymorphisms are important with
respect to the different outcomes of H. pylori infections, we studied
their effects on gastric physiology in healthy subjects. We had
previously shown that a cohort of 149 ®rst-degree relatives of gastric
cancer patients from the West of Scotland had a high prevalence of
hypochlorhydria (de®ned as a pentagastrin-stimulated peak acid
output of less than 15 mmol h-1) in association with H. pylori
infection23. Of the 103 (69%) gastric cancer relatives (GCR) infected
with the H. pylori, 45 had hypochlorhydria and gastric atrophy and
58 had normal or high acid secretion. One hundred unselected
newborns from the West of Scotland were available as population
controls. We also had available a case-control study of gastric cancer,
based on a population from Warsaw, Poland, in which there were
393 gastric cancer cases and 430 controls with DNA samples24. We
were thus able to determine whether genotypes that modify IL-1b
are associated with low acid secretion and gastric atrophy, and
whether these same genotypes increase the risk of gastric cancer.
These studies were reviewed and approved by the Institutional
Review Boards and Ethics Committees of the US National Cancer
Institute, the University of Glasgow Hospitals NHS Trust, and the
M. Sklodowska-Curie Memorial Cancer Centre (Warsaw).
In both the Scottish and Polish control populations, the alleles at
the individual loci of IL-1B and IL-1RN were in Hardy±Weinberg
equilibrium, with non-signi®cant x2 values. There was marked
linkage disequilibrium among the loci within the gene cluster (see
also ref. 25). Linkage disequilibrium between IL-1B 2 31 and
IL-1B 2 511 was almost total, with 99.5% of the inferred haplotypes
(IL-1B 2 31=IL-1B 2 511) in the combined control groups consist-
ing of either T±T or C±C (Table 1). There was also strong linkage
disequilibrium (D9 < 0:5) between IL-1B 2 31 and IL-1RN in both
populations. However, the two groups differed with respect to
linkage disequilibrium between IL-1B 2 31 and IL-1B  3954,
which was strong in the Scottish population controls but relatively
weak (D9  2 0:16) in the Polish controls. There was no signi®cant
linkage disequilibrium between IL-1B  3954 and IL-1RN in either
control group.
There were no signi®cant differences in genotype frequency for
any IL-1 marker between the GCR and controls or between the total
H. pylori-infected and uninfected GCR (Table 2). Nevertheless,
among the infected GCR, those with low acid secretion had a
signi®cantly higher frequency of the pro-in¯ammatory IL-1RN*2
allele and the T±T haplotype of IL-1B 2 31 and IL-1B 2 511
(IL-1B 2 31T=1L-1B 2 511T), as compared with the GCR with
normal or high acid secretion. Carriers of the T allele of
IL-1B 2 31 (IL-1B 2 31T) had an age-adjusted odds ratio of 9.1
(95% con®dence interval (CI), 2.2±37), and there was little differ-
ence between the homozygous and heterozygous carriers (Table 2).
IL-1RN*2 homozygotes (IL-1RN*2/*2) were also at increased risk of
hypochlorhydria, although risk among the IL-1RN*2 heterozygotes
was not signi®cantly increased (Table 2). In a logistic regression
model including both factors, the estimated age-adjusted odds
ratios for IL-1B 2 31T and IL-1RN*2/*2 were 7.5 (95% CI, 1.8±
31) and 2.1 (95% CI, 0.7±6.3), respectively. The IL-1B  3954
genotype was not associated with the risk of hypochlorhydria.
There were similar associations between these alleles and the risk
of gastric cancer. Carriers of IL-1B 2 31T had an increased gastric
cancer risk at an odds ratio of 1.9 (95% CI, 1.5±2.6), with no
signi®cant difference between homozygotes and heterozygotes
(Table 3). Moreover, IL-1RN*2 was associated with an increased
risk in homozygotes but not in heterozygotes (Table 3). In a logistic
regression model including both of these genotypes, the estimated
odds ratios for IL-1B 2 31T and IL-1RN*2/*2 were 1.6 (95% CI,
1.2±2.2) and 2.9 (95% CI, 1.9±4.4), respectively. IL-1B  3954T
homozygotes seemed to be protected against gastric cancer,
although the effect did not reach statistical signi®cance (Table 3).
The estimated effects of IL-1B 2 31T and IL-1RN*2/*2 were
similar in subgroups of gastric cancer cases de®ned by age, sex,
histological type and anatomical site (data not shown). Further-
more, adjustment for other reported risk factors for gastric cancer,
including tobacco and alcohol use, ABO blood group and family
history of gastric cancer, did not substantially alter the estimates
(data not shown).
The IL-1B 2 31T=IL-1RN*2 haplotype imparted a greatly
increased risk of gastric cancer, as compared with having no copy
of IL-1B 2 31T and at least one copy of the other IL-1RN alleles.
Twenty-two per cent of cases (compared with eight per cent of
controls) had this haplotype, either in its homozygous form or with
IL-1B 2 31C=IL-1RN*2, with an odds ratio of 4.4 (95% CI, 2.8±6.9).
In the absence of IL-1B 2 31T, homozygous IL-1RN*2 was asso-
ciated with a similarly elevated odds ratio of 5.3 (95% CI, 1.9±14),
although this genotype combination was uncommon because of
linkage disequilibrium between the two loci. In contrast, the odds
ratio for IL-1B 2 31T with no more than one copy of IL-1RN*2
was only 1.7 (95% CI, 1.2±2.3). Nonetheless, because its effect is
observed in both homozygotes and heterozygotes, the IL-1B 2 31T
allele accounts for a greater proportion of excess gastric cancer cases
than the IL-1RN*2 allele, despite their comparable frequencies. The
Table 2 IL-1 genotype frequencies in gastric cancer relatives (GCR) and controls
H. pylori-infected GCR
Locus Genotype Low acid
(n  45)
Normal acid
(n  58)
Odds ratio
(95% CI)*
Uninvected GCR
(n  46)
Population controls
(n  100)
...................................................................................................................................................................................................................................................................................................................................................................
IL-1B 2 31 C/C 5 30 1.0 23 37
C/T 28 21 8.1 (2.0±33) 18 50
T/T 12 7 13.6 (2.6±71) 5 13
IL-1B 2 511 C/C 5 29 1.0 23 36
C/T 30 21 8.3 (2.0±34) 18 51
T/T 10 8 11.4 (2.2±58) 5 13
IL-1B  3954 C/C 30 35 1.0 28 67
C/T 15 23 0.8 (0.3±1.9) 15 26
T/T 0 0 3 7
IL-1RN 1/1 17 35 1.0 24 42
1/2 14 14 2.4 (0.9±6.2) 15 44
1/3, 4, 5 0 2 0 0 2
2/2 14 7 5.6 (1.8±17) 7 12
...................................................................................................................................................................................................................................................................................................................................................................
* Odds ratio for low acid versus normal/high acid, adjusted for age and within-family sampling. CI, con®dence interval.
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fraction of gastric cancer in the population that is attributable to
IL-1B 2 31T is estimated to be 31%, compared with 18% for IL-
1RN*2. Their combined population attributable fraction is esti-
mated to be 38%, which represents the fraction of gastric cancer
cases that are caused by these IL-1 alleles.
The IL-1B 2 31 polymorphism involves a TATA sequence in the
IL-1B promoter. To investigate the effect of IL-1B 2 31 variants on
the induction of IL-1b, we used electrophoretic mobility-shift
analysis to assess their DNA-binding activity in vitro. Synthetic
allele-speci®c oligonucleotides representing the polymorphic
IL-1B 2 31 sites were incubated with nuclear protein extracts
from non-stimulated human monocytes and monocytes activated
by lipopolysaccharide (LPS). LPS stimulation induced a ®vefold
increase in DNA binding (complex 1) on the IL-1B 2 31T oligonu-
cleotide (Fig. 1, lanes 1 and 2). In contrast, LPS failed to induce
complex 1 formation on the IL-1B 2 31C oligonucleotide (Fig. 1,
lanes 5 and 6). Furthermore, complex 1 formation on radiolabelled
IL-1B 2 31T was speci®cally blocked by competition with the
unlabelled IL-1B 2 31T, but not the IL-1B 2 31C, oligonucleotide
(Fig. 1, lanes 3 and 4). These results indicate that one or more
proteins (presumably transcription factors) in complex 1 may be
unable to interact with the C-bearing IL-1B 2 31 allele to form the
transcription initiation complex. In parallel experiments assessing
allele-speci®c oligonucleotides for IL-1B 2 511, there were no
differences in binding activity (data not shown), indicating that
the effect of IL-1B 2 511 may be mediated by linkage disequilibrium
with the TATA box polymorphism. On the basis of these results and
previously published functional data for IL-1RN, hypochlorhydria
and gastric cancer may be associated with alleles of IL-1B 2 31 and
IL-1RN that enhance IL-1b production.
Here we demonstrate that pro-in¯ammatory genotypes of the IL-
1 loci (IL-1B 2 31T and IL-1RN*2/*2) increase both the like-
lihood of a chronic hypochlorhydric response to H. pylori infection
and the risk of gastric cancer, presumably by altering IL-1b levels in
the stomach. While the pro-in¯ammatory effects of high IL-1b
concentrations may facilitate the clearance of H. pylori from the
gastric mucosa, the concomitant inhibition of acid secretion allows
the spread of H. pylori-induced in¯ammation from the antrum to
the corpus. This functional inhibition is initially reversible but the
progressive destruction of parietal cells eventually leads to irrever-
sible hypochlorhydria. A decreased ¯ow of gastric secretions may
therefore heighten mucosal damage by allowing the accumulation
of bacterial toxins and by-products of in¯ammation that would
normally be diluted and ¯ushed out. The reactive oxygen and
nitrogen oxide species that are derived from in¯ammation are
known mutagens, while hypochlorhydria permits superinfection
by other bacteria that enhance the production of highly car-
cinogenic N-nitroso compounds26.
H. pylori-induced hypochlorhydria also markedly reduces the
levels of vitamin C in gastric juice27, further facilitating the forma-
tion of N-nitroso compounds. The opportunities for DNA damage
caused by this cascade of genotoxic factors are ampli®ed by the
increased rate of cell turnover in in¯amed mucosa. Therefore,
genotypes that enhance IL-1b production may favour the initiation
of a set of responses to H. pylori that result in hypochlorhydria,
corpus atrophy and an increased risk of gastric cancer.
Our ®ndings complement the most widely accepted multi-stage
model of gastric carcinogenesis4, and provide insights into the
etiological role of H. pylori. We have shown at least two suscept-
ibility loci in the IL-1 gene cluster for gastric cancer and its
precursors. The effects of these loci in¯uence an early stage of the
disease process and require the presence of H. pylori infection.
Progression towards cancer is probably in¯uenced by other com-
ponents of the host genetic constitution acting epistatically, as well
as by dietary and other factors in the environment.
IL-1B 2 31T=IL-1RN*2 constitutes a pro-in¯ammatory haplotype
that is in strong linkage disequilibrium, at least in Caucasian
populations. We speculate that this linkage disequilibrium re¯ects
past selective pressures for or against enhancement of the IL-1b
response to environmental challenges. Whereas pro-in¯ammatory
genotypes may be advantageous for the host response to some
infections, the vigorous IL-1b production associated with H. pylori
gastric infection may exacerbate mucosal damage and increase the
risk of eventual neoplasia. M
Methods
IL-1 genotyping
IL-1B polymorphisms were distinguished by two separate methods, polymerase chain
reaction single-strand conformation polymorphism (PCR-SSCP) and 59 nuclease PCR
assays (TaqMan). For PCR-SSCP, 50 ng DNA was ampli®ed in a GeneAmp PCR System
9700 (PE Applied Biosystems), using the primer pairs listed in the Supplementary
Information. Ampli®cation was performed in a volume of 20 ml, containing 10 mM Tris-
HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 200 mM each of dATP, dTTP and dGTP, 100 mM
dCTP, 1 mCi of [a-32P]dCTP (3,000 Ci mol-1), 80 ng of each primer and 1 unit of Taq
polymerase. The thermocycling conditions were as follows: 94 8C for 10 min; then 5 cycles
of 94 8C for 30 s, 65 8C for 30 s and 72 8C for 30 s; then 30 cycles of 94 8C for 30 s, 60 8C for
30 s and 72 8C for 30 s; then 5 cycles of 94 8C for 30 s, 55 8C for 30 s and 72 8C for 30 s. SSCP
analysis of the radiolabelled ampli®cation products was performed as described28.
For TaqMan assays, primers (Operon Technologies Inc.) and probes (PE Applied
Biosystems) were designed using Primer Express software (PE Applied Biosystems).
Probes for the T or C allele were 59-labelled with either FAM (6-carboxy¯uoresceine) or
VIC ¯uorogenic dyes, and 39-labelled with TAMRA (6-carboxytetramethylrhodamine)
quencher. PCR ampli®cation was performed in a volume of 25 ml containing 50 ng
genomic DNA, 1´ TaqMan Universal Master Mix (PE Applied Biosystems), 200 nM for
each probe and 900 nM for primers. Cycling conditions were 50 8C for 2 min, 95 8C for
10 min, then 40 cycles of 95 8C for 15 s and 62 8C for 1 min, as recommended by the
manufacturer. Thermal cycling of optical plates was performed in GeneAmp PCR System
9700 and endpoint analysis was performed in the ABI PRISM 7700 Sequence Detection
System (PE Applied Biosystems). Sequences of primers and probes for IL-1B TaqMan
assays are available from the authors.
For IL-1RN, genomic DNA was ampli®ed using PCR under the conditions described
above for IL-1B, using forward primer 59-CCCCTCAGCAACACTCC-39 and reverse
primer 59-GGTCAGAAGGGCAGAGA-39. The PCR products were separated by electro-
phoresis on 2% agarose gels and stained with ethidium bromide. Alleles were sized relative
to a 1-kb DNA ladder and coded conventionally as follows: allele 1  4 repeats,
allele 2  2 repeats, allele 3  5 repeats, allele 4  3 repeats, allele 5  6 repeats; the
rarer alleles 3, 4 and 5 were grouped in the statistical analysis.
A total of 93% (366/393) of the gastric cancer cases, 99% (429/430) of their population
controls, and all GCR subjects and their newborn population controls were successfully
genotyped for all four loci.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from freshly isolated human monocytes as described29,
after no stimulation or addition of 1 mg ml-1 LPS derived from E. coli (Sigma) for 30 min.
Complementary single-stranded oligonucleotides were synthesized (Life Technologies) as
follows (variant nucleotides in bold):
IL-1B 2 31 : 59-TGCTTTTGAAAGCC=TATAAAAACAGCG-39
IL-1B 2 511 : 59-TGACAGAGAGCTCCC=TGAGGCAGAGAAC-39
Complementary strands were annealed by combining 2 mg of each oligonucleotide and
6 ml of 10´ annealing buffer (500 mM Tris, 100 mM MgCl2 and 50 mM dithiothreitol) in a
60-ml reaction, placing in a boiling water bath for 5 min and allowing to cool to room
temperature. The DNA±protein binding reaction was conducted in a 20-ml volume
containing 7 mg of nuclear protein extract, 1 mg poly (dI±dC) (Sigma), 4 ml of 5´ binding
Table 3 IL-1 genotype frequencies in gastric cancer cases and controls
Locus Genotype Cases
(n  366)
Controls
(n  429)
Odds ratio
(95% CI)
.............................................................................................................................................................................
IL-1B 2 31 C/C 128 219 1.0
C/T 172 164 1.8 (1.3±2.4)
T/T 66 46 2.5 (1.6±3.8)
IL-1B 2 511 C/C 127 217 1.0
C/T 170 166 1.8 (1.3±2.4)
T/T 69 46 2.6 (1.7±3.9)
IL-1B  3954 C/C 212 242 1.0
C/T 140 158 1.0 (0.8±1.4)
T/T 14 29 0.6 (0.3±1.1)
IL-1RN 1/1 148 230 1.0
1/2 117 152 1.2 (0.9±1.6)
1/3, 4, 5 8 7 1.8 (0.7±4.8)
2/2 93 39 3.7 (2.4±5.7)
2/5 0 1 0
.............................................................................................................................................................................
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buffer (60 mM HEPES, 7.5 mM MgCl2, 300 mM KCl, 1 mM ethylenediamine-tetraacetic
acid, 2.5 mM dithriothreitol, 50% glycerol and 4-(2-aminoethyl)-benzenesulphonyl
¯uoride hydrochloride) and 2:5 3 104 c:p:m: of 32P-labelled oligonucleotide probe. UN-
SCAN-IT 5.1 software (Silk Scienti®c) was used for densitometric analysis of the
autoradiographs.
Statistical analysis
Hardy±Weinberg equilibrium of alleles at individual loci was assessed by x2 statistics.
Haplotype frequencies for pairs of alleles were estimated using the Estimating Haplotype-
frequencies (EH) software program (ftp://linkage.rockefeller.edu/software/eh). Linkage
disequilibrium coef®cients D9  D=Dmax and x
2 values were calculated for pairs of the
most common alleles at each locus using the LINKDOS software program (distributed
with GENEPOP, ftp://ftp.cefe.cnrs-mop.fr/pub/PC/MSDOS/GENEPOP/). Odds radios
with Corn®eld 95% con®dence intervals and logistic regression models controlling for the
effects of possible confounders were computed using STATA version 5.0 software (STATA
Press). The odds ratios for hypochlorhydria were age-adjusted (categorized as <35, 36±
45, 46±55 and .55 years) because of its age-dependence23 and their con®dence intervals
were based on robust variance estimates30 which adjust for within-family correlation, to
account for sampling of several members of a given family.
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Productive interaction of a T lymphocyte with an antigen-pre-
senting cell results in the clustering of the T-cell antigen receptor
(TCR) and the recruitment of a large signalling complex to the site
of cell±cell contact1,2. Subsequent signal transduction resulting in
cytokine gene expression requires the activation of one or more of
the multiple isoenzymes of serine/threonine-speci®c protein
kinase C (PKC)3. Among the several PKC isoenzymes expressed
in T cells, PKC-u is unique in being rapidly recruited to the site of
TCR clustering4. Here we show that PKC-u is essential for TCR-
mediated T-cell activation, but is dispensable during TCR-depen-
dent thymocyte development. TCR-initiated NF-kB activation
was absent from PKC-v-/- mature T lymphocytes, but was intact
in thymocytes. Activation of NF-kB by tumour-necrosis factor a
and interleukin-1 was unaffected in the mutant mice. Although
studies in T-cell lines had suggested that PKC-u regulates activa-
tion of the JNK signalling pathway5,6, induction of JNK was
normal in T cells from mutant mice. These results indicate that
PKC-u functions in a unique pathway that links the TCR signal-
ling complex to the activation of NF-kB in mature T lymphocytes.
We inactivated the gene encoding PKC-u by homologous recom-
bination in embryonic stem cells by replacing the exon encoding the
ATP-binding site of the kinase domain (amino-acid residues 396±
451) with the neomycin resistance gene. Homozygous mutant mice
seemed normal and were fertile. Immunoblot analysis with anti-
bodies directed against sequences outside the deleted coding region
of PKC-u failed to detect any protein product, even of smaller than
normal size, in thymocytes or T cells from the mutant animals (data
not shown). Flow cytometric analyses of cells from thymus, spleen
and lymph nodes of the mutant mice were indistinguishable from
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